|  | Webcast
Q3 2008 MDRNA, Inc. Earnings Conference Call (Replay)
11/13/08 at 4:30 p.m. ET |
At MDRNA we are focused on realizing the potential of RNAi-based therapeutics through the development of a broad-based, state-of-the-art drug discovery platform built upon industry leading expertise in RNA chemistry and oligonucleotide delivery. We bring optimal value to our partners, shareholders and ultimately to patients through the discovery and development of RNAi-based therapeutics against human diseases including critical unmet medical needs in areas such as cancer, metabolic disorders and inflammation. More >>
|  | |
|
|
| Date | Title | | | 11/13/08 | MDRNA, Inc. Announces Third Quarter 2008 Financial Results| BOTHELL, WA, Nov 13, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the
three- and nine-month periods ended September 30, 2008.
Revenue for the three months ended September 30, 2008 was $0.4
million, compared to $1.9 million for the three months ended September
30, 2007. Revenue for the nine months ended September 30, 2008 was
$2.4 million, compared to $11.7 million for the nine months ended
September 30, 2007. Revenue in 2008 ... |
|  | | 11/06/08 | MDRNA, Inc. to Hold Third Quarter 2008 Earnings Conference Call on Thursday, November 13, 2008, at 4:30 p.m. Eastern Time| BOTHELL, WA, Nov 06, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a
conference call with investors and security analysts on Thursday,
November 13, 2008, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
to discuss financial results for the third quarter ended September
30, 2008. To participate in the live conference call, U.S. residents
should dial 800-573-4754 and international callers should dial
617-224-4325. The participant... |
| | | 10/28/08 | MDRNA, Inc. Appoints Barry Polisky, Ph.D., as Chief Scientific Officer| Names New Chairman of the Board and Chair of the Scientific Advisory BoardBOTHELL, WA, Oct 28, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that Barry Polisky,
Ph.D., will join the Company as Chief Scientific Officer on January
2, 2009. Dr. Polisky replaces Steven C. Quay, M.D., Ph.D., Chief
Scientific Officer, Chairman of the Board of Directors and Chairman
of the Scientific Advisory Board, who will be leaving the Company on
November 30, 2008. Dr... |
| | | 10/22/08 | MDRNA, Inc. Acquires Patent Estate to Broaden Its RNAi Intellectual Property Portfolio| Acquires Rights to UNA Technology for Proprietary Stabilization of Both RISC and Dicer siRNAsBOTHELL, WA, Oct 22, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has acquired
intellectual property related to non-nucleotide chemistry (Unlocked
Nucleic Acid) technology from RiboTask ApS, a privately held Danish
company specializing in the development and synthesis of novel RNA
chemistries. The technology will permit MDRNA to stabilize and
provi... |
| |
|
|
| Primary IR Contact | Matt Haines
Senior Director, Investor Relations and Corporate Communications
MDRNA Inc.
Phone: 212-209-3874
E-mail: ir@mdrnainc.com |
| | | Transfer Agent | American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
Phone: 877-777-0800
Corporate Website: http://www.amstock.com
|
| | Legal | Pryor Cashman Sherman & Flynn LLP
410 Park Avenue
New York, NY 10022
Phone: (212) 421-4100
Corporate Website: http://www.pryorcashman.com
|
| | | Accountants | KPMG
3100 Two Union Square
801 Second Avenue
Seattle, WA 98104
Phone: 206-292-1500
Corporate Website: http://www.kpmgcampus.com
|
|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
